Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - recombinant omega interferon of feline origin - parenteral liquid/solution/suspension - recombinant omega interferon of feline origin vaccine active 10.0 mu/ml - immunotherapy - cat | dog - adult | cat - queen | cat - tom | kitten - canine parvovirus | feline calicivirus | calicivirus (feline) | fcv | parvovirus

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

alissa healthcare research ltd - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 2 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

fresenius kabi usa, llc - fish oil (unii: xgf7l72m0f) (fish oil - unii:xgf7l72m0f) - omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (pnac). limitations of use: - omegaven is not indicated for the prevention of pnac. it has not been demonstrated that omegaven prevents pnac in parenteral nutrition (pn)-dependent patients [see clinical studies (14)]. - it has not been demonstrated that the clinical outcomes observed in patients treated with omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product [see clinical studies (14)]. use of omegaven is contraindicated in patients with: - known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients [see warnings and precautions (5.2)]. - severe hemorrhagic disorders due to a potential effect on platelet aggregation. - severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations greater than 1,000 mg/dl) [see warnings and precautions (5.6)]. risk summary there are no av

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - colecalciferol,concentrated fish omega-3 triglycerides -

Eiropas Savienība - angļu - EMA (European Medicines Agency)

virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.